Accuray Incorporated has announced that the company received 510(k) clearance from the FDA for its new CyberKnife M6 Series. The CyberKnife M6 Series features expanded clinical capabilities and reduced treatment times. The new CyberKnife M6 FIM and FM Systems, featuring the InCise Multileaf Collimator combines the benefits of beam-shaping with the flexibility of nonisocentric, noncoplanar delivery, offering unmatched clinical capabilities and expanding the number of patients eligible for treatment.
The new InCise Multileaf Collimator was designed specifically for stereotactic radiosurgery and stereotactic body radiation therapy treatments, giving the system the capability to extend its radiosurgical accuracy into a broader field of applications, meeting radiosurgery and radiotherapy needs. With the InCise Multileaf Collimator, the CyberKnife M6 Series can be used to treat large and irregular tumors with more efficient dose gradients. This added flexibility expands the number of patients eligible for treatment with the CyberKnife M6 Series. ■
